Tech Company Financing Transactions

REGENXBIO Funding Round

Brookside Capital and Venrock participated in a $30 million Series C venture round for REGENXBIO. The round closed on 1/22/2015.

Transaction Overview

Company Name
Announced On
1/22/2015
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors

Brookside Capital (Lead Investor)

Venrock (Lead Investor) (Camille Samuels)

Proceeds Purpose
REGENXBIO plans to use the proceeds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, and expand its team.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9600 Blackwell Rd. 210
Rockville, MD 20850
USA
Email Address
Not Recorded
Overview
REGENXBIO (NASDAQ: RGNX) is leveraging our proprietary NAV Technology to advance the development of life-changing adeno-associated viral (AAV) gene therapy treatments for lysosomal storage disorders and ocular diseases.
Profile
REGENXBIO LinkedIn Company Profile
Social Media
REGENXBIO Company Twitter Account
Company News
REGENXBIO News
Facebook
REGENXBIO on Facebook
YouTube
REGENXBIO on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ken Mills
  Ken Mills LinkedIn Profile  Ken Mills Twitter Account  Ken Mills News  Ken Mills on Facebook
Chief Financial Officer
Vit Vasista
  Vit Vasista LinkedIn Profile  Vit Vasista Twitter Account  Vit Vasista News  Vit Vasista on Facebook
Chief Medical Officer
Stephen Yoo
  Stephen Yoo LinkedIn Profile  Stephen Yoo Twitter Account  Stephen Yoo News  Stephen Yoo on Facebook
Chief Scientific Officer
Olivier Danos
  Olivier Danos LinkedIn Profile  Olivier Danos Twitter Account  Olivier Danos News  Olivier Danos on Facebook
Chief Technical Officer
Curran Simpson
  Curran Simpson LinkedIn Profile  Curran Simpson Twitter Account  Curran Simpson News  Curran Simpson on Facebook
VP - General Counsel
Patrick Christmas
  Patrick Christmas LinkedIn Profile  Patrick Christmas Twitter Account  Patrick Christmas News  Patrick Christmas on Facebook
VP - Human Resources
Shiva Fritsch
  Shiva Fritsch LinkedIn Profile  Shiva Fritsch Twitter Account  Shiva Fritsch News  Shiva Fritsch on Facebook
VP - Operations
Ram Palanki
  Ram Palanki LinkedIn Profile  Ram Palanki Twitter Account  Ram Palanki News  Ram Palanki on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/22/2015: Selvera venture capital transaction
Next: 1/22/2015: XOR Data Exchange venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary